Impact of non-pharmaceutical interventions for reducing transmission of COVID-19: a systematic review and meta-analysis protocol.
Impact of non-pharmaceutical interventions for reducing transmission of COVID-19: a systematic review and meta-analysis protocol.
复制标题
DOI：
10.1136/bmjopen-2020-041383
复制
发表时间：
2020-10-22
期刊：
影响因子：
2.9
通讯作者：
Lwin CM
中科院分区：
文献类型：
--
作者：
Regmi K;Lwin CM
实施非药物干预措施（NPI）保护公众免受COVID-19的影响。然而，非盈利机构的影响并不一致，仍然不清楚。因此，本研究旨在衡量主要NPI（社交距离、社交隔离和隔离）对减少COVID-19传播的影响。我们将对随机和非随机对照试验进行系统回顾和荟萃分析研究。我们将进行系统的搜索：MEDLINE，Embase，Allied & Complementary Medicine，COVID-19 Research，WHO COVID-19数据库，ClinicalTrails.Gov for clinical trials on COVID-19，科克伦冠状病毒资源（COVID-19）、牛津COVID-19 Evidence Service和Google Scholar，以获取有关COVID-19的已发表和未发表文献，包括medRxiv、bioRxiv、Litcovid和SSRN用于未发表的COVID-19研究，并将根据系统性综述和荟萃分析的首选报告项目进行报告。影响分析的关注结果将包括减少COVID-19传播、避免人群聚集和限制行动、隔离疾病和心理影响。本方案使用了系统性综述和荟萃分析方案检查表的首选报告项目。对于纳入研究的质量，我们将使用科克伦协作组的工具评估随机对照试验的偏倚风险，并使用Newcastle-Ottawa量表评估观察性研究。建议评估、开发和评价方法的分级将对研究中所有结局指标的证据确定性进行分级。荟萃分析的随机效应模型将测量NPI的效应量或关系的强度。对于定量数据，将计算风险比或OR、绝对风险差（对于二分结局数据）或平均差或标准化平均差（对于连续数据）及其95% CI。如果无法进行统计汇总，则将对纳入的研究进行叙述性综合。为了评估效应的异质性，将评价I2和观察到的效应，以提供分析中的真实效应。由于不会收集主要数据，因此不需要机构审查委员会或研究伦理委员会的正式伦理批准。本研究的最终结果将发表在开放获取的同行评审期刊上，摘要将在适当的国家/国际会议或研讨会上发表。我们还将与公共卫生当局以及世卫组织分享重要信息。此外，我们可能会将提交的审阅稿件发布到medRxiv或其他相关的预印本服务器。CRD 42020207338。
Implementing non-pharmaceutical interventions (NPIs) protect the public from COVID-19. However, the impact of NPIs has been inconsistent and remains unclear. This study, therefore, aims to measure the impact of major NPIs (social distancing, social isolation and quarantine) on reducing COVID-19 transmission. We will conduct a systematic review and meta-analysis research of both randomised and non-randomised controlled trials. We will undertake a systematic search of: MEDLINE, Embase, Allied & Complementary Medicine, COVID-19 Research, WHO database on COVID-19, ClinicalTrails.Gov for clinical trials on COVID-19, Cochrane Resources on Coronavirus (COVID-19), Oxford COVID-19 Evidence Service and Google Scholar for published and unpublished literatures on COVID-19 including preprint engines such as medRxiv, bioRxiv, Litcovid and SSRN for unpublished studies on COVID-19 and will be reported in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Outcomes of interest for impact analysis will include the reduction of COVID-19 transmission, avoiding crowds and restricting movement, isolating ill and psychological impacts. The Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols checklist has been used for this protocol. For quality of included studies, we will use the Cochrane Collaboration’s tool for assessing risk of bias for randomised controlled trials and the Newcastle-Ottawa Scale for observational studies. The Grading of Recommendations Assessment, Development and Evaluation approach will grade the certainty of the evidence for all outcome measures across studies. Random-effects model for meta-analysis will measure the effect size of NPIs or the strengths of relationships. For quantitative data, risk ratio or OR, absolute risk difference (for dichotomous outcome data), or mean difference or standardised mean difference (for continuous data) and their 95% CIs will be calculated. Where statistical pooling is not possible, a narrative synthesis will be conducted for the included studies. To assess the heterogeneity of effects, I2 together with the observed effects will be evaluated to provide the true effects in the analysis. Formal ethical approval from an institutional review board or research ethics committee is not required as primary data will not be collected. The final results of this study will be published in an open-access peer-reviewed journal, and abstract will be presented at suitable national/international conferences or workshops. We will also share important information with public health authorities as well as with the WHO. In addition, we may post the submitted manuscript under review to medRxiv, or other relevant preprint servers. CRD42020207338.
登录
查看更多内容
影响因子：
2
作者：
Jackson, Dan
通讯作者：
Jackson, Dan
影响因子：
56.3
作者：
Koo, Joel R.;Cook, Alex R.;Dickens, Borame L.
通讯作者：
Dickens, Borame L.
影响因子：
105.7
作者：
Egger, M;Smith, GD;Minder, C
通讯作者：
Minder, C
影响因子：
50
作者：
Bayham, Jude;Fenichel, Eli P.
通讯作者：
Fenichel, Eli P.
影响因子：
4.5
作者：
Ahmed F;Zviedrite N;Uzicanin A
通讯作者：
Uzicanin A